Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

29.27 -0.84 (-2.79%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Surmodics's Return On Capital Employed Insights
Via Benzinga
Surmodics, Inc. (NASDAQ:SRDX) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 02/07/2023 -- An investigation was announced over potential securities laws violations by Surmodics, Inc. in connection with certain financial statements. 
Via SBWire
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Earnings Outlook For Surmodics
Via Benzinga
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics Stock Slides Following Regulatory Setback For Its SurVeil Drug-Coated Balloon
Via Benzinga
Earnings Scheduled For February 6, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. 
Via Benzinga
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
From Surmodics, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From Rosen Law Firm
Via Business Wire
Dow Drops 150 Points; Crude Oil Up 1%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 150 points on Thursday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 29 stocks made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. 
Via Benzinga
Nasdaq Down Over 100 Points; Procter & Gamble Posts In-Line Earnings
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 300 points on Thursday. 
Via Benzinga
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday. 
Via Benzinga
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
From Surmodics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
From Surmodics, Inc.
Via Business Wire
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
From Surmodics, Inc.
Via Business Wire
Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing
From Surmodics, Inc.
Via Business Wire
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
From Surmodics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.